Advicenne announces the launch of its new website
PARIS–(BUSINESS WIRE)–Regulatory News:
Advicenne (Euronext Growth Paris ALDVI – FR0013296746), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced the launch of its new website, www.advicenne.com.
The new website aims to offer better ergonomics and to provide more accurate and complete information, particularly on:
– Information intended for all its shareholders.
– The Company’s approved and/or marketed products or those sold under license (Sibnayal®, ADV6209, Likozam®, Levidcen®).
– Rare renal pathologies targeted by Advicenne, in particular dRTA and Cystinuria.
– The development pipeline.
Didier Laurens, Chief Executive Officer of Advicenne, said: “Of course, our business is to offer innovative treatments to patients affected by kidney diseases for which there is no effective therapeutic solution. But this new website also marks an important step for the Company, which has been moving into a new phase for several months now: the marketing of Sibnayal® in Europe and beyond, either on its own or through commercial partnerships with pharmaceutical companies. I am sure that our new website will better reflect our transformation”.
About Advicenne
Advicenne (Euronext Growth Paris ALDVI – FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product SibnayalTM (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information see: https://advicenne.com/.
Disclaimer
This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2021 Universal Registration Document filed with the French financial market authority on April 29, 2022 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
Contacts
Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: [email protected]
Consilium Strategic Communications
Mary-Jane Elliott, Ashley Tapp, Davide Salvi
+44 (0)20 3709 5700
Email: [email protected]
Ulysse Communication
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: [email protected]
